Pegfilgrastim biosimilar (Hospira)

培非格司亭生物类似药（Hospira）

Report date: 2024/01/15 10:54:59

Base Information

Drug NamePegfilgrastim biosimilar (Hospira)
Drug Alias Namepegfilgrastim-apgf培非拉司亭生物仿制药（辉瑞）聚乙二醇非格司亭生物仿制药（辉瑞）Pegfilgrastimum (Pfizer)培非司亭生物仿制药（辉瑞） +[7] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsFebrile NeutropeniaNeutropeniaLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsFebrile NeutropeniaNeutropenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/06/10
Country/TerritoryUnited StatesHungaryAustralia +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHospiraPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteHospira IncPfizer Europe Ma Eeig
Inactive CompaniesHospiraPfizer Inc
Active IndicationsFebrile NeutropeniaNeutropeniaLymphoma, Large B-Cell, Diffuse +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AA13
Related LinksN/A